1-3 of 3
Johan Jansson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results

Yi-Bin Chen, MD, Nirav N Shah, MD, Anne S. Renteria, MD, Corey S. Cutler, MD MPH, Johan Jansson, PhD, Mona Akbari, MD, Chunlin Chen, MD PhD, Syed Quadri, MD, Andrejus Parfionovas, PhD, Steven Devine
Journal: Blood
Blood (2018) 132 (Supplement 1): 605.
https://doi.org/10.1182/blood-2018-99-111143
Published: 2018
Journal Articles

Leukemia Free Survival Is Associated with Presence of Leukemia Reactive Antibodies In Allogeneic Transplant Recipients

Craig A. Mullen, MD, PhD, Yu-Chiao Hsu, MS, Andrew Campbell, MS, Johan Jansson, Ph.D., Olena Tkachenko, M.D.
Journal: Blood
Blood (2010) 116 (21): 2534.
https://doi.org/10.1182/blood.V116.21.2534.2534
Published: 2010
Journal Articles

Acute Lymphoblastic Leukemia Cells Adapt to Post-Transplant Alloreactivity by Upregulating Sca-1.

Jessica C Shand, MD, Andrew Campbell, BS, Johan Jansson, Craig A. Mullen, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1195.
https://doi.org/10.1182/blood.V112.11.1195.1195
Published: 2008